Loading stock data…
$1.16+0.00 (+0.43%)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Spero Therapeutics, Inc. in the Healthcare sector is trading at $1.16 with a market capitalization of $69M. Wall Street consensus targets $5.00 (2 analysts), implying a +332.9% move over the next 12 months. The stock is currently near its 52-week low of $1.08, remaining 43.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $258,000↓ | $39.66M↑ | $3.05M↓ | $11.80M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.93M↓ | -$7.54M↓ | $31.41M↑ | -$7.33M↓ | -$2.36M |
| Net Income | -$9.55M↓ | -$7.20M↓ | $31.52M↑ | -$7.38M↓ | -$1.70M |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates ...